ArticleFrontiers in medicine2026

Ravulizumab for relapse prevention in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report.

Nabil Akkawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.